The DOI matches its Crossref record; 43 of the 44 references it cites were found in a registry or an index.
Fibrillar amyloid-β burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease
Open accessAbstract
Fibrillar amyloid-beta (Aβ) is found in the brains of many cognitively normal older people. Whether or not this reflects a predisposition to Alzheimer's disease (AD) is unknown. We used Pittsburgh Compound B (PiB) PET to characterize the relationship between fibrillar Aβ burden and this predisposition in cognitively normal older people at 3 mean levels of genetic risk for AD. Dynamic PiB PET scans, the Logan method, statistical parametric mapping, and automatically labeled regions of interest (ROIs) were used to characterize and compare cerebral-to-cerebellar PIB distribution volume ratios, reflecting fibrillar Aβ burden, in 28 cognitively normal persons (mean age, 64 years) with a reported family history of AD and 2 copies, 1 copy, and no copies of the apolipoprotein E (APOE) ε4 allele. The 8 ε4 homozygotes, 8 heterozygotes, and 12 noncarriers did not differ significantly in terms of age, sex, or cognitive scores. Fibrillar Aβ was significantly associated with APOE ε4 carrier status and ε4 gene dose in AD-affected mean cortical, frontal, temporal, posterior cingulate-precuneus, parietal, and basal ganglia ROIs, and was highest in an additional homozygote who had recently developed mild cognitive impairment. These findings suggest that fibrillar Aβ burden in cognitively normal older people is associated with APOE ε4 gene dose, the major genetic risk factor for AD. Additional studies are needed to track fibrillar Aβ accumulation in persons with different kinds and levels of AD risk; to determine the extent to which fibrillar Aβ, alone or in combination with other biomarkers and risk factors, predicts rates of cognitive decline and conversion to clinical AD; and to establish the role of fibrillar Aβ imaging in primary prevention trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Crossing a transgenic mouse model of AD that has high levels of human Aβ in the brain with human APOE targeted replacement mice demonstrated age-dependent and APOE isoform-dependent (E4>>E3>E2) Aβ deposition and amyloid burden in the brain in a manner that recapitulates the human condition observed in pre-symptomatic elderly APOE4 carriers as well as AD patients.18–21”
From AAVrh.10-Mediated APOE2 Central Nervous System Gene Therapy for APOE4-Associated Alzheimer's Disease (2018) · cites this paper as [20]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the amyloid deposition spreads, and the disease pathogenesis progressively involves a broad region of the brain”
From AAVrh.10-Mediated APOE2 Central Nervous System Gene Therapy for APOE4-Associated Alzheimer's Disease (2018) · cites this paper as [20]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The association of the APOE4 isoform with amyloid deposition has been well established in human studies, where APOE4 carriers exhibit higher A β plaque burden and earlier onset of amyloid positivity compared with non-carriers 35 -37 .”
From APOE2 attenuates APOE4-associated amyloid pathology and related toxicity in a mouse model of Alzheimer’s disease (2026) · cites this paper as [37]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“APOE status has been found to modulate the onset of extracellular amyloid plaque deposition, one of the key pathognomonic features of the disease (6, 7).”
From Human ApoE isoforms differentially regulate brain amyloid-β peptide clearance (2011) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Additionally, the APOE ε4 allele increases brain amyloid burden assessed by PIB-PET imaging in a gene dose-dependent manner (6).”
From Human ApoE isoforms differentially regulate brain amyloid-β peptide clearance (2011) · cites this paper as [6]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“APOE isoform-dependent amyloid deposition has been consistently observed in humans and Aβ depositing mouse models (Holtzman et al., 2000; Bales et al., 2009; Reiman et al., 2009; Morris et al., 2010).”
From Haploinsufficiency of Human APOE Reduces Amyloid Deposition in a Mouse Model of Amyloid-β Amyloidosis (2011) · cites this paper as Reiman et al., 2009
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The ε4 allele increased brain amyloid burden in a dose-dependent manner in normal elderly individuals and in mild cognitive impairment patients [93,94].”
From Plasma levels of apolipoprotein E, APOE genotype and risk of dementia and ischemic heart disease: A review (2016) · cites this paper as [93]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“This finding has now been confirmed more directly in a study that showed cognitively normal subjects had an ε4 dose-dependent increase in fibrillar Aβ burden in brain as detected with an amyloid imaging agent (Reiman et al., 2009).”
From The role of apolipoprotein E in Alzheimer's disease (2009) · cites this paper as Reiman et al., 2009
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“This possibility has remained unaddressed, because case–control studies without neuropathological or biomarker assessments of AD may have underestimated the impact of APOE genotypes on Alzheimer’s dementia ORs due to the confounding effects of APOE genotypes on the percentages of neuropathologically misclassified cases and controls8–10.”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [9]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Due to the prioritized ascertainment of those cases who met the clinical and neuropathological criteria for Alzheimer’s dementia and those unimpaired controls without AD, the number of misclassified cases and controls available through the AD Genetics Consortium12 is much smaller than our estimated number of neuropathologically misclassified cases and controls8–11, limiting our ability to clarify”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [9]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In a previous autopsy study, we found that 25% of persons with the clinical diagnosis of mild-to-moderate Alzheimer’s dementia lacked at least moderately frequent neuritic plaques, one of the cardinal features of AD, including 37% of APOE4 non-carriers and 13% of carriers, findings that are consistent with those in living patients9,10.”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [9]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
Tzourio-Mazoyer, N., Landeau, B., Papathanassiou, D., Crivello, F., Etard, O., Delcroix, N., Mazoyer, B., & Joliot, M. (2002) · NeuroImage · doi:10.1006/nimg.2001.0978 · Cited by 16,319
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Co-Planar Stereotaxic Atlas of the Human Brain
Talairach, J., & Tournoux, P. (1988) · Medical Entomology and Zoology · Cited by 11,798
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429
Co-planar stereotaxic atlas of the human brain
Laitinen, L. (1989) · Clinical Neurology and Neurosurgery · doi:10.1016/0303-8467(89)90128-5 · Cited by 7,565
Winblad, B., Palmer, K., Kivipelto, M., Jelic, V., Fratiglioni, L., Wahlund, L. ‐., Nordberg, A., Bäckman, L., Albert, M., Almkvist, O., et al. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01380.x · Cited by 4,946
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496
Self-citationStrittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1977 · Cited by 4,268 · cited 1×
“The APOE 4 allele is associated with increased cerebral and vascular A deposition in AD (25), and the ApoE E4 isoform is associated with increased A binding, fibrillization, and cerebral and vascular A deposition (13, 26), as well as with decreased ApoE-mediated A clearance and degradation (27–29).”
BackgroundRestriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI.
Hixson, J., & Vernier, D. (1990) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)43176-1 · Cited by 2,933
Flagged first, then by citations
1 of the 44 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 601–700 of 787
Yun, R., Lin, C., Wu, S., Huang, C., Lin, C., & Chao, Y. (2013) · Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC) · doi:10.1109/embc.2013.6609553 · Cited by 7
Apolipoprotein E, Neurodegeneration, and Alzheimer Disease
Jagust, W. J. (2012) · JAMA Neurology · doi:10.1001/jamaneurol.2013.726 · Cited by 7
Molecular genetics of early-onset Alzheimer's disease and frontotemporal lobar degeneration
Krüger, J. (2010) · Cited by 7
Network-targeted transcranial magnetic stimulation (TMS) for mild cognitive impairment (MCI)
Taylor, J. L., Bhatt, P., Hernandez, B., Iv, M., Adamson, M. M., Heath, A. M., Yesavage, J. A., & McNerney, M. W. (2025) · NeuroImage Clinical · doi:10.1016/j.nicl.2025.103819 · Cited by 6
APOE4 modulates the association between DTI‐ALPS index and Alzheimer's pathologies
Ks, K., Park, C., Byun, M. S., Yi, D., Nam, H., Ryu, J., Jung, J. H., Jung, G., Ahn, H., Lee, J., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70837 · Cited by 6
Xue, R., Gao, P., Chen, Y.-M., Liu, Y., Han, B., Huang, Y., Mi, Y., Cui, R., Lin, Y., Wang, Z.-T., et al. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251322808 · Cited by 6
Kikis, E. A. (2017) · Healthcare · doi:10.3390/healthcare5030046 · Cited by 6
Clinical Biomarkers and Novel Drug Targets to Cut Gordian Knots of Alzheimer's Disease
Mir, R. H., Masoodi, M. H., Shah, A. J., Mohi-ud-din, R., Sabreen, S., Wani, T. U., Jan, R., Javed, M. N., & Mir, P. A. (2022) · Current Molecular Pharmacology · doi:10.2174/1874467215666220903095837 · Cited by 6
Fungwe, T. V., Ngwa, J. S., Johnson, S. P., Turner, J. V., Ramirez-Ruiz, M., Ogunlana, O., Bedada, F. B., Nadarajah, S., Ntekim, O. E., & Obisesan, T. O. (2023) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000528117 · Cited by 5
Positron Emission Tomography in Alzheimer Disease
Schmidt, M. E., Matthews, D. C., Andrews, R. D., & Mosconi, L. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-386945-6.00005-6 · Cited by 7
The Role of Genetics in Alzheimer's Disease and Parkinson's Disease
Porter, T., Gozt, A., Mastaglia, F. L., & Laws, S. M. (2019) · Wiley eBooks · doi:10.1002/9781119356752.ch15 · Cited by 6
Vahid, A., Zamani, J., & Hosseini, S. M. H. (2025) · npj Dementia · doi:10.1038/s44400-025-00041-z · Cited by 5
Plasma GFAP as a mediator and moderator of Aβ, tau, and neurodegeneration in Alzheimer’s disease
Kim, J. S., Yi, D., Byun, M. S., Ahn, H., Jung, G., Choi, H., Lee, J., Kang, K. M., Chul-Ho, S., Lee, Y.-S., et al. (2026) · npj Dementia · doi:10.1038/s44400-025-00051-x · Cited by 5
Donev, R., & Howell, O. W. (2012) · Advances in protein chemistry and structural biology · doi:10.1016/b978-0-12-394287-6.00004-5 · Cited by 5
Statistical inference models for image datasets with systematic variations
Kim, W. H., Bendlin, B. B., Chung, M. K., Johnson, S. C., & Singh, V. (2015) · IEEE Computer Society Conference on Computer Vision and Pattern Recognition/Proceedings - IEEE Computer Society Conference on Computer Vision and Pattern Recognition/Proceedings · doi:10.1109/cvpr.2015.7299112 · Cited by 5
Mikos, A. E., Piryatinsky, I., Tremont, G. N., & Malloy, P. F. (2012) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e318266c6c3 · Cited by 5
Genetic Variants and Related Biomarkers in Sporadic Alzheimer’s Disease
Guerreiro, R. J., Brás, J., Toombs, J., Heslegrave, A., Hardy, J., & Zetterberg, H. (2014) · Current Genetic Medicine Reports · doi:10.1007/s40142-014-0062-6 · Cited by 6
Altered lipid metabolic homeostasis in the pathogenesis of Alzheimer’s disease
Marian, O. C., Tran, C., & Don, A. S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819404-1.00023-3 · Cited by 5
Luckett, E. S., Schaeverbeke, J. M., Meyer, S. D., Adamczuk, K., Laere, K. V., Dupont, P. J., & Vandenberghe, R. R. (2022) · NeuroImage Clinical · doi:10.1016/j.nicl.2023.103321 · Cited by 5
Mattsson, P., Forsberg, A., Persson, J., Nyberg, L. H., Nilsson, L., Halldin, C., & Farde, L. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-015-3103-9 · Cited by 6
Neuroimaging of Alzheimer’s Disease, Mild Cognitive Impairment, and Other Dementias
Risacher, S. L., & Saykin, A. J. (2010) · Springer eBooks · doi:10.1007/978-1-4419-6373-4_19 · Cited by 5
Masdeu, J. C. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-375000-6.00127-0 · Cited by 5
Unraveling APOE4's Role in Alzheimer's Disease: Pathologies and Therapeutic Strategies
Tripathi, S., Sharma, Y., & Kumar, D. (2024) · Current Protein and Peptide Science · doi:10.2174/0113892037326839241014054430 · Cited by 5
Huang, S., Nunez, J., Toresco, D. L., Wen, C., Slotabec, L. A., Wang, H., Zhang, H., Rouhi, N., Adenawoola, M. I., & Li, J. (2025) · The FASEB Journal · doi:10.1096/fj.202402725rr · Cited by 4
Cha, W.-J., Chumin, E. J., Yi, D., Byun, M. S., Jung, J. H., Ahn, H., Jung, G., Kim, Y. K., Lee, Y., Kang, K. M., et al. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71025 · Cited by 5
Microbial Trojan Horses: Virulence Factors as Key Players in Neurodegenerative Diseases
Grahl, M. V. C., Hohl, K. S., Smaniotto, T. Â., & Carlini, C. R. (2025) · Molecules · doi:10.3390/molecules30030687 · Cited by 5
Moderation of midlife cognitive activity on tau‐related cognitive impairment
Ko, K., Yi, D., Byun, M. S., Jung, J. H., Kong, N., Jung, G., Ahn, H., Chang, Y. Y., Keum, M., Lee, J., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14606 · Cited by 4
Leite, J., Hespanhol, R., & Buchpiguel, C. A. (2014) · Neuroimaging Clinics of North America · doi:10.1016/j.nic.2014.09.005 · Cited by 4
Park, D. C., & Farrell, M. E. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-411469-2.00005-4 · Cited by 4
Shu, H., Chen, G., Ward, B. D., Chen, G., Wang, Z., Liu, D., Su, F., Gu, L., Xu, Z., Li, S., et al. (2021) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-021-01310-7 · Cited by 4
Lee, D., Park, J., Jung, K. S., Kim, J., Jang, J. S., Kwon, S., Byun, M. S., Yi, D., Byeon, G., Jung, G., et al. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00719-3 · Cited by 6
Choo, I. H., Chong, A., Chung, J. Y., Ha, J., Choi, Y. Y., & Kim, H. (2022) · Psychiatry Investigation · doi:10.30773/pi.2022.0014 · Cited by 4
Kim, J. W. (2022) · Aging and Disease · doi:10.14336/ad.2022.1118 · Cited by 4
Aβ Imaging in Aging, Alzheimer’s Disease and Other Neurodegenerative Conditions
Villemagne, V. L., Fodero‐Tavoletti, M. T., Yates, P. A., Masters, C. L., & Rowe, C. C. (2014) · Springer eBooks · doi:10.1007/978-3-642-54307-4_10 · Cited by 4
Does an Alzheimer's disease susceptibility gene influence the cognitive effects of cancer therapy?
Caselli, R. J. (2013) · Pediatric Blood & Cancer · doi:10.1002/pbc.24768 · Cited by 4
Self-citationShin, M., Kweon, S., Choi, J., Lee, Y. H., Nam, H., Park, K.-S., Kim, H. N., Oh, S., & Jeong, S. (2014) · Disease Markers · doi:10.1155/2014/724281 · Cited by 4
Kim, J. W., Byun, M. S., Yi, D., Lee, J. H., Ko, K., Jung, G., & Lee, D. Y. (2019) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s192231 · Cited by 4
Using Pittsburgh Compound B For Pet Imaging Across the Alzheimer’s Disease Spectrum
Cohen, A. D. (2016) · Technology & Innovation · doi:10.21300/18.1.2016.51 · Cited by 4
Farias, F., Benítez, B. A., & Cruchaga, C. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105247 · Cited by 4
Staneva, G., Yordanova, V., Danailova, A., Marinovska, A.-M., Dér, A., & Taneva, S. G. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262311361 · Cited by 3
Shining a Light on Phenotypic Drug Discovery
Hsu, K. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.01.020 · Cited by 3
alzheimer disease: New Concepts on Its Neurobiology and the Clinical
Jack, C. R., & Cme, O. (2012) · Cited by 3
Rohn, T. T., Beck, J. D., Galla, S. J., Isho, N. F., Pollock, T. B., Suresh, T., Kulkarni, A., Sanghal, T., & Hayden, E. J. (2021) · International Journal of Neurodegenerative Disorders · doi:10.23937/2643-4539/1710020 · Cited by 3
Byeon, G., Byun, M. S., Yi, D., Ahn, H., Jung, G., Lee, Y., Kim, Y. K., Kang, K. M., Sohn, C., & Lee, D. Y. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240380 · Cited by 3
Tau pathway‐based gene analysis on PET identifies CLU and FYN in a Korean cohort
Yi, D., Byun, M. S., Park, J., Kim, J., Jung, G., Ahn, H., Lee, J., Lee, Y., Kim, Y., Kang, K. M., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14416 · Cited by 3
The Use of Antihypertensive Medication and In Vivo Alzheimer's Disease Pathology
Keum, M., Byun, M. S., Yi, D., Ahn, H., Jung, G., Jung, J. H., Kong, N., Lee, J., Kim, Y., Lee, Y., et al. (2025) · Annals of Neurology · doi:10.1002/ana.27204 · Cited by 3
Klinisch-validierte molekulare Biomarker neurodegenerativer Demenzerkrankungen
Wiltfang, J. (2014) · Der Nervenarzt · doi:10.1007/s00115-014-4086-7 · Cited by 3
18F-THK 5351 and 11C-PiB PET of the Thai normal brain template.
Chotipanich, C., Kongthai, S., Kunawudhi, A., Promteangtrong, C., & Jantarato, A. (2021) · Europe PMC (PubMed Central) · doi:10.22038/aojnmb.2020.49623.1338 · Cited by 3
Brain Imaging in Behavioral Medicine and Clinical Neuroscience: Synthesis
Cohen, R. A., & Sweet, L. H. (2010) · Springer eBooks · doi:10.1007/978-1-4419-6373-4_23 · Cited by 3
Osherovich, L. Z. (2009) · Science-Business eXchange · doi:10.1038/scibx.2009.962 · Cited by 2
The ABCA7 transporter, brain lipids and Alzheimer’s disease
Soscia, S. J., & Fitzgerald, M. L. (2013) · Clinical Lipidology · doi:10.2217/clp.12.91 · Cited by 3
Neuropathology of HIV-1 Disease
Soontornniyomkij, V. (2017) · Springer eBooks · doi:10.1007/978-1-4939-7290-6_8 · Cited by 3
Choo, I. H., Chong, A., Chung, J. Y., & Kim, H. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190816 · Cited by 3
Wang, X., Zhang, F., Cui, Y., Zheng, L., & Yan, W. (2017) · PubMed Central · Cited by 3
PET Imaging of Amyloid and Tau in Alzheimer’s Disease
Okamura, N., & Harada, R. (2022) · Springer eBooks · doi:10.1007/978-981-16-7977-3_19 · Cited by 3
Age-Related Memory Decline and the APOE ε4 Effect
Ma, L., Zhao, G., & Feng, X. (2009) · New England Journal of Medicine · doi:10.1056/nejmc091640 · Cited by 3
Ferguson, C. M., Hildebrand, S. R., Godinho, B. M. D. C., Buchwald, J. E., Echeverria, D., Coles, A. H., Grigorenko, A. P., Vanjielli, L., Sousa, J., McHugh, N., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.06.28.498012 · Cited by 3
Situmeang, R., Wahjoepramono, E. J., Kaelan, C., Purba, J. S., Suhadi, B., As’ád, S., Aliah, A., Patellongi, I. J., & Wahid, S. (2016) · Medical Journal of Indonesia · doi:10.13181/mji.v25i1.1255 · Cited by 2
Jones, T. B., Chu, P., Wilkey, B., Lynch, L. M., & Jentarra, G. M. (2024) · Brain Sciences · doi:10.3390/brainsci14070677 · Cited by 3
Impact of APOE4‐related dementia risk in underrepresented groups from the All of Us research program
Ghisays, V., Khajouei, E., Piras, I. S., Malek‐Ahmadi, M. H., Protas, H. D., Goradia, D. D., Chen, Y., Naymik, M., Saner, D., Veatch, O. J., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70245 · Cited by 2
Self-citationFree-water imaging of the nucleus basalis of Meynert in apolipoprotein E4 carriers
Ofori, E., Braden, B. B., Chen, K., Su, Y., Caselli, R. J., & Reiman, E. M. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1597127 · Cited by 2
Self-citationKim, M., Byun, M. S., Yi, D., Ahn, H., Jung, G., Jung, J. H., Chang, Y. Y., Kim, K., Choi, H., Choi, J., et al. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261418688 · Cited by 2
Imaging Biomarkers for Diagnosis, Prognosis and Treatment of Alzheimer's Disease
Skovronsky, D., & Feuerstein, G. (2012) · Frontiers in neuroscience · doi:10.1201/b11986-4 · Cited by 2
Distinct Cognitive Trajectories According to Amyloid Positivity in Non-Alzheimer Disease Dementias
Jang, H., Chun, M. Y., Yun, J., Kim, J. P., Kang, S. H., Kim, H. J., Na, D. L., Lee, E. H., Shin, D., Ham, H., et al. (2024) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000005457 · Cited by 2
Telomere length, in vivo Alzheimer’s disease pathologies and cognitive decline in older adults
Jung, J. H., Byun, M. S., Yi, D., Ahn, H., Lee, J. H., Lee, J.-S., Lee, H., Lee, J., Kim, Y. K., Lee, Y., et al. (2024) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2024-334314 · Cited by 2
What Can We Learn From Regional Vulnerability to amyloid-β Accumulation in Nondemented individuals?
Shinohara, M., & Bu, G. (2013) · Neurodegenerative Disease Management · doi:10.2217/nmt.13.20 · Cited by 2
Defining Neurocognitive Disorders
McDonald, W. M. (2011) · American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e31823497c7 · Cited by 2
Amyloid imaging for Alzheimer's disease
Kerchner, G. A. (2011) · Expert Opinion on Medical Diagnostics · doi:10.1517/17530059.2011.617365 · Cited by 2
Lipid metabolism in the central nervous system and neurodegenerative diseases
Hayashi, H. (2011) · Folia Pharmacologica Japonica · doi:10.1254/fpj.137.227 · Cited by 2
Huang, S., Zhu, J., Shen, X., Xu, W., Ma, Y., Li, H., Dong, Q., Tan, L., & Yu, J. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200059 · Cited by 2
Aβ42-α7-like nicotinic acetylcholine receptors and Alzheimer’s disease
Wang, H.-Y., & Khan, A. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-815868-5.00029-3 · Cited by 2
Moon, S. W., Byun, M. S., Yi, D., Kim, M. J., Jung, J. H., Kong, N., Jung, G., Ahn, H., Lee, J., Kang, K. M., et al. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-220911 · Cited by 2
Ofori, E., Vaillancourt, D. E., Greig‐Custo, M. T., Barker, W., Hanson, K., DeKosky, S. T., Garvan, C. S., Adjouadi, M., Golde, T. E., Loewenstein, D., et al. (2023) · Brain Imaging and Behavior · doi:10.1007/s11682-023-00819-w · Cited by 3
Self-citationIntroduction to Alzheimer’s Disease
Manivasagam, T., Surya, R., Jayalakshmi, M., Thenmozhi, A. J., Prema, A., Qoronfleh, M. W., Alharbi, H. F., & Rajamani, Y. (2023) · Nutritional neurosciences · doi:10.1007/978-981-99-0677-2_1 · Cited by 2
Wissenschaftliche Neurobildgebung in der Medizin
Weiller, C., Meyer, P. T., & Hennig, J. (2010) · Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz · doi:10.1007/s00103-010-1096-x · Cited by 1
Zhang, H., Chiu, P. W., Ip, I. N., Liu, T., Wong, G. H. Y., Song, Y., Wong, S. W. H., Herrup, K., & Mak, H. K. (2021) · European Journal of Neuroscience · doi:10.1111/ejn.15399 · Cited by 1
Aβ Imaging in Aging, Alzheimer’s Disease, and Other Neurodegenerative Conditions
Villemagne, V. L., Doré, V., Burnham, S. C., & Rowe, C. C. (2020) · Springer eBooks · doi:10.1007/978-3-030-53168-3_10 · Cited by 2
Development of a Cognitive Composite for Preclinical Alzheimer’s Disease in Korean Older Adults
Kim, M., Yi, D., Byun, M. S., Ahn, H., Jung, J. H., Kong, N., Chang, Y., Choi, H., Choi, J.-M., Kim, K. T., et al. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230263 · Cited by 2
Visual and Auditory Sensory Impairments Differentially Relate with Alzheimer’s Pathology
Byeon, G., Byun, M. S., Yi, D., Jung, J. H., Kong, N., Chang, Y., Keum, M., Jung, G., Ahn, H., Lee, J., et al. (2024) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.24.1169 · Cited by 1
Koivumäki, M., Martiskainen, H., Takalo, M., Lehtisalo, J., Ngandu, T., FinnGen, Snellman, A., Hiltunen, M. O., & Rinne, J. O. (2026) · Alzheimer s Research & Therapy · doi:10.1186/s13195-026-01984-y · Cited by 1
Cell-type-specific APOE4 cascade across the Alzheimer’s disease continuum
Shostak, D. M., Liang, Z., & Huang, Y. (2026) · Neuron · doi:10.1016/j.neuron.2026.04.024 · Cited by 1
MRI- and PET-Based Imaging Markers for the Diagnosis of Alzheimer’s Disease
Teipel, S. J., Sperling, R. A., Skudlarski, P., Jack, C. R., Hampel, H. J., Fellgiebel, A., & Herholz, K. (2012) · Advances in biological psychiatry · doi:10.1159/000335393 · Cited by 1
Genetic Risk Factors: Their Function and Comorbidities in Alzheimer′s Disease
Hiltunen, M. O., Bertram, L., & Saunders, A. J. (2011) · International Journal of Alzheimer s Disease · doi:10.4061/2011/925362 · Cited by 1
Amyloid PET: Its diagnostic potential compared to FDG
Herholz, K. (2011) · Médecine Nucléaire · doi:10.1016/j.mednuc.2011.02.007 · Cited by 1
Ashraf, A., Mehta, P. D., & Edison, P. (2012) · Reviews in Clinical Gerontology · doi:10.1017/s0959259812000160 · Cited by 1
Augmenting Cognitive Reserve of Dementia Patients with Brain Aerobics
Zmily, A., & Mashal, E. (2014) · Lecture notes in computer science · doi:10.1007/978-3-319-09891-3_29 · Cited by 1
Biomarkers for Alzheimer's Dementia : Focus on Neuroimaging
Won, W. Y., & Lee, C. U. (2011) · Saengmul jeongsin euihag/Saengmul jeongsin uihak · Cited by 1
Revisiting the genetics of APOE
Carmona, S., Kun‐Rodrigues, C., Brás, J., & Guerreiro, R. J. (2017) · UCL Discovery (University College London) · Cited by 1
ROLE OF SOD AND CATHEPSIN-D IN ALZHEIMER’S DISEASE Aβ CASCADE MODELS
Lobdell, G. M., & Donahue, M. K. (2011) · Digital WPI · Cited by 1
Basics of amyloid β-protein in Alzheimer’s disease
Sugimoto, A., & Ono, K. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-89906-2.00012-5 · Cited by 1
Role of light walking pace on cognition: Findings from the Maine-Syracuse Longitudinal Study
Ahmed, F. S., Guenther, B. A., Thompson, J. L., Lagerstrom, L., & Robbins, M. A. (2023) · Applied Neuropsychology Adult · doi:10.1080/23279095.2023.2228952 · Cited by 1
Shifting Paradigm in Early Detection and Prediction of Alzheimer's Disease
Bashir, T., Akhouri, D., & Hamza, H. (2024) · Advances in medical technologies and clinical practice book series · doi:10.4018/979-8-3693-1090-8.ch013 · Cited by 1
Daily fluid intake and brain amyloid deposition: A cohort study
Kim, J. W., Byun, M. S., Yi, D., Jung, J. H., Kong, N., Chang, Y. Y., Jung, G., Ahn, H., Lee, J., Kang, K. M., et al. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251314176 · Cited by 1
Functional and Structural MRI in Alzheimer’s Disease: A Multimodal Approach
Grothe, M. J., Bokde, A. L. W., & Teipel, S. J. (2014) · Springer eBooks · doi:10.1007/978-3-642-54542-9_20 · Cited by 1
Early Diagnosis and Risk of Conversion from Presymptomatic Stages
Menéndez‐González, M. (2014) · Springer eBooks · doi:10.1007/978-3-319-07989-9_1 · Cited by 1
Amyloid Imaging in Dementia and Related Disorders
Camacho, V., & Carrió, I. (2016) · Springer eBooks · doi:10.1007/978-3-319-31614-7_7 · Cited by 1
Resting State Glucose Utilization and Adult Reading Test Performance
Lee, Y., Yi, D., Seo, E. H., Han, J., Joung, H., Byun, M. S., Lee, J. H., Jun, J., & Lee, D. Y. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00048 · Cited by 1
What are we willing to accept for preventing Alzheimer's disease? – Investigators' reply
Tariot, P. N., Langbaum, J. B. S., & Reiman, E. M. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)30055-2 · Cited by 1
Self-citationMethod development for extraction and HPLC analysis of kaempferol, chrysin and quercetin
Ludick, N. J. J. (2020) · Boloka Institutional Repository (North-west University) · Cited by 1
APOE4 alters the lipid droplet proteome and modulates droplet dynamicsPreprint
Friday, C. M., Stephens, I. O., Smith, C. T., Lee, S., Satish, D., Devanney, N. A., Cohen, S., Morganti, J. M., Gordon, S. M., & Johnson, L. A. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.12.16.628710 · Cited by 1
Metadata
- Authors
- Reiman, E. M., Chen, K., Liu, X., Bandy, D., Yu, M., Lee, W., Ayutyanont, N., Keppler, J., Reeder, S. A., Langbaum, J. B. S., Alexander, G. E., Klunk, W. E., Mathis, C. A., Price, J. C., Aizenstein, H. J., DeKosky, S. T., & Caselli, R. J.
- Affiliations
- Translational Genomics Research Institute (US)
- Banner - University Medical Center Phoenix (US)
- University of Arizona (US)
- Departments of iPsychiatry,
- University of Pittsburgh (US)
- Mayo Clinic in Arizona (US)
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2009-04-21
- Volume
- 106
- Issue
- 16
- Pages
- 6820-6825
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC2665196
- OpenAlex
- W2171346860
- Semantic Scholar
- 50d5adab23ba1a800626a6f613f94a2c667b07e4
- Cited by
- 785
- References
- 44
- Citations by year
- 2026: 15 · 2025: 26 · 2024: 34 · 2023: 36 · 2022: 36 · 2021: 45 · 2020: 44 · 2019: 39 · 2018: 34 · 2017: 34 · 2016: 40 · 2015: 50 · 2014: 66 · 2013: 61 · 2012: 65
- FWCI
- 45.56
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- McKnight Foundation
- National Institute on Aging (R01AG025526, R01AG018402, P01AG025204, RF1AG025516, P50AG005133, R01AG031581, P30AG019610, R37AG025516)
- National Institute of Mental Health (R01MH070729, R01MH057899)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- fibrillar amyloid-beta, Alzheimer's disease, APOE ε4, genetic risk, cognitively normal older adults, Pittsburgh compound B PET, family history of Alzheimer's disease, mild cognitive impairment, primary prevention
- MeSH terms
- Aged, Alzheimer Disease, Brain Mapping, Cognition, Heterozygote, Homozygote, Humans, Magnetic Resonance Imaging, Middle Aged, Neuropsychological Tests, Amyloid beta-Peptides, Gene Dosage, Genetic Predisposition to Disease, Apolipoprotein E4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
